What is the next earnings date for ABIO stock?
ARCA BIOPHARMA INC (ABIO) will report earnings on 2024-10-16, after the market close.
ARCA BIOPHARMA INC (ABIO) Forecast, Price Target & Analyst Ratings
NASDAQ:ABIO • US00211Y5069
Current stock price
2.4 USD
-0.1 (-4%)
At close:
2.48 USD
+0.08 (+3.33%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ARCA BIOPHARMA INC (ABIO).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
$0.00
Upside
-100.00%
From current price of $2.40 to mean target of $0.00, Based on 7 analyst forecasts
Low
$0.00
Median
$0.00
High
$0.00
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
ABIO was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about ABIO.
In the previous month the buy percentage consensus was at a similar level.
ABIO was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Oct 16, 2024
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates 2024 - 2026
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | ||||||||||
| EBITDA YoY % growth | -11.44M | -16.59M -45.02% | -18.68M -12.60% | -8.1M 56.64% | -5.79M 28.52% | -9.76M -68.57% | -19.319M -97.94% | -10.576M 45.26% | -7.281M 31.16% | N/A | N/A | N/A | |
| EBIT YoY % growth | -11.46M | -16.61M -44.94% | -18.71M -12.64% | -8.12M 56.60% | -5.81M 28.45% | -9.77M -68.16% | -19.335M -97.90% | -10.596M 45.20% | -7.296M 31.14% | N/A | N/A | N/A | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -10.08 71.85% | -4.53 55.06% | -2.50 44.81% | N/A | N/A | N/A | N/A | N/A -20.51% | N/A -30.50% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
ARCA BIOPHARMA INC / ABIO Forecast FAQ
Can you provide the consensus rating for ARCA BIOPHARMA INC stock?
The consensus rating for ARCA BIOPHARMA INC (ABIO) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.